25 XP   0   0   10

Guiyang Xintian Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Guiyang Xintian Pharmaceutical Co Ltd together

PenkeI guess you are interested in Guiyang Xintian Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Guiyang Xintian Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Guiyang Xintian Pharmaceutical Co Ltd

I send you an email if I find something interesting about Guiyang Xintian Pharmaceutical Co Ltd.

Quick analysis of Guiyang Xintian Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of Guiyang Xintian Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
¥0.04
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥5.16
Expected worth in 1 year
¥5.96
How sure are you?
94.7%

+ What do you gain per year?

Total Gains per Share
¥1.08
Return On Investment
8.6%

For what price can you sell your share?

Current Price per Share
¥12.58
Expected price per share
¥9.59 - ¥14.33
How sure are you?
50%

1. Valuation of Guiyang Xintian Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

¥12.58

Intrinsic Value Per Share

¥1.55 - ¥1.89

Total Value Per Share

¥6.71 - ¥7.04

2. Growth of Guiyang Xintian Pharmaceutical Co Ltd (5 min.)




Is Guiyang Xintian Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$165.4m$131.4m$28.9m18.0%

How much money is Guiyang Xintian Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$3.4m$4m-$610.1k-17.8%
Net Profit Margin10.1%10.3%--

How much money comes from the company's main activities?

3. Financial Health of Guiyang Xintian Pharmaceutical Co Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#291 / 1031

Most Revenue
#167 / 1031

Most Profit
#106 / 1031

Most Efficient
#122 / 1031

What can you expect buying and holding a share of Guiyang Xintian Pharmaceutical Co Ltd? (5 min.)

Welcome investor! Guiyang Xintian Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of Guiyang Xintian Pharmaceutical Co Ltd.

What can you expect buying and holding a share of Guiyang Xintian Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of Guiyang Xintian Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Guiyang Xintian Pharmaceutical Co Ltd is ¥12.58. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Guiyang Xintian Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Guiyang Xintian Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥5.16. Based on the TTM, the Book Value Change Per Share is ¥0.20 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.07 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Guiyang Xintian Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.020.2%0.010.1%0.010.1%0.010.1%0.010.1%
Usd Book Value Change Per Share0.020.2%0.030.2%0.020.1%0.040.3%0.040.3%
Usd Dividend Per Share0.000.0%0.010.1%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.030.2%0.040.3%0.020.2%0.040.3%0.040.3%
Usd Price Per Share1.77-1.89-2.51-2.33-2.33-
Price to Earnings Ratio17.91-41.82-51.22-88.53-88.53-
Price-to-Total Gains Ratio66.62-66.62-600.43-144.61-144.61-
Price to Book Ratio2.48-2.73-4.45-4.60-4.60-
Price-to-Total Gains Ratio66.62-66.62-600.43-144.61-144.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.741072
Number of shares574
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share0.030.04
Usd Total Gains Per Share0.040.04
Gains per Quarter (574 shares)21.3924.39
Gains per Year (574 shares)85.5697.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1226476118688
24412716223172186
36619124834259284
48825533445345382
511031842057431480
613238250668517578
715344559279604676
817550967891690774
9197573764102776872
10219636850113862970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%17.02.00.089.5%17.02.00.089.5%17.02.00.089.5%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%19.00.00.0100.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%18.01.00.094.7%18.01.00.094.7%18.01.00.094.7%

Fundamentals of Guiyang Xintian Pharmaceutical Co Ltd

About Guiyang Xintian Pharmaceutical Co Ltd

Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines for various diseases in China. The company offers formulation products, which include hard capsules, granules, tablets, mixtures, syrups, liquors, dews, powders, suspensions, and gels. Its products are used for the treatment of anti-tumor, gynecological, urological diseases, breast thyroid, blood supplement, heat clearing type, oral, anti-cold, and cardiovascular diseases. Guiyang Xintian Pharmaceutical Co.,Ltd. was founded in 1995 and is based in Guiyang, China.

Fundamental data was last updated by Penke on 2024-03-11 01:23:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Guiyang Xintian Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Guiyang Xintian Pharmaceutical Co Ltd earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Guiyang Xintian Pharmaceutical Co Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 16.6% means that ¥0.17 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 16.6%. The company is making a huge profit. +2
  • The TTM is 10.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ16.6%TTM10.1%+6.5%
TTM10.1%YOY10.3%-0.1%
TTM10.1%5Y9.9%+0.2%
5Y9.9%10Y9.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.6%-159.2%+175.8%
TTM10.1%-202.3%+212.4%
YOY10.3%-263.0%+273.3%
5Y9.9%-452.4%+462.3%
10Y9.9%-589.0%+598.9%
1.1.2. Return on Assets

Shows how efficient Guiyang Xintian Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Guiyang Xintian Pharmaceutical Co Ltd to the Biotechnology industry mean.
  • 2.0% Return on Assets means that Guiyang Xintian Pharmaceutical Co Ltd generated ¥0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 2.0%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.0%TTM1.2%+0.7%
TTM1.2%YOY1.8%-0.6%
TTM1.2%5Y1.6%-0.3%
5Y1.6%10Y1.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0%-12.5%+14.5%
TTM1.2%-12.2%+13.4%
YOY1.8%-11.2%+13.0%
5Y1.6%-13.3%+14.9%
10Y1.6%-14.6%+16.2%
1.1.3. Return on Equity

Shows how efficient Guiyang Xintian Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Guiyang Xintian Pharmaceutical Co Ltd to the Biotechnology industry mean.
  • 3.5% Return on Equity means Guiyang Xintian Pharmaceutical Co Ltd generated ¥0.03 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 3.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.5%TTM2.1%+1.3%
TTM2.1%YOY3.0%-0.9%
TTM2.1%5Y2.7%-0.6%
5Y2.7%10Y2.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5%-16.0%+19.5%
TTM2.1%-15.8%+17.9%
YOY3.0%-13.9%+16.9%
5Y2.7%-18.2%+20.9%
10Y2.7%-19.1%+21.8%

1.2. Operating Efficiency of Guiyang Xintian Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Guiyang Xintian Pharmaceutical Co Ltd is operating .

  • Measures how much profit Guiyang Xintian Pharmaceutical Co Ltd makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Guiyang Xintian Pharmaceutical Co Ltd to the Biotechnology industry mean.
  • An Operating Margin of 20.9% means the company generated ¥0.21  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 20.9%. The company is operating efficient. +1
  • The TTM is 8.6%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ20.9%TTM8.6%+12.3%
TTM8.6%YOY8.7%-0.1%
TTM8.6%5Y10.5%-2.0%
5Y10.5%10Y10.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.9%-299.5%+320.4%
TTM8.6%-208.5%+217.1%
YOY8.7%-280.2%+288.9%
5Y10.5%-459.9%+470.4%
10Y10.5%-596.9%+607.4%
1.2.2. Operating Ratio

Measures how efficient Guiyang Xintian Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.02 means that the operating costs are ¥1.02 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 1.016. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.103. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.016TTM1.103-0.087
TTM1.103YOY1.086+0.017
TTM1.1035Y1.092+0.011
5Y1.09210Y1.0920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0162.817-1.801
TTM1.1033.181-2.078
YOY1.0863.609-2.523
5Y1.0925.554-4.462
10Y1.0927.396-6.304

1.3. Liquidity of Guiyang Xintian Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Guiyang Xintian Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.25 means the company has ¥1.25 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 1.251. The company is just able to pay all its short-term debts.
  • The TTM is 1.229. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.251TTM1.229+0.022
TTM1.229YOY1.344-0.116
TTM1.2295Y1.567-0.338
5Y1.56710Y1.5670.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2513.987-2.736
TTM1.2294.440-3.211
YOY1.3445.569-4.225
5Y1.5676.158-4.591
10Y1.5676.492-4.925
1.3.2. Quick Ratio

Measures if Guiyang Xintian Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Guiyang Xintian Pharmaceutical Co Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.62 means the company can pay off ¥0.62 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 0.623. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.579. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.623TTM0.579+0.043
TTM0.579YOY0.714-0.135
TTM0.5795Y0.736-0.157
5Y0.73610Y0.7360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6233.653-3.030
TTM0.5794.158-3.579
YOY0.7145.515-4.801
5Y0.7366.012-5.276
10Y0.7366.206-5.470

1.4. Solvency of Guiyang Xintian Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Guiyang Xintian Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Guiyang Xintian Pharmaceutical Co Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.42 means that Guiyang Xintian Pharmaceutical Co Ltd assets are financed with 42.3% credit (debt) and the remaining percentage (100% - 42.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 0.423. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.405. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.423TTM0.405+0.018
TTM0.405YOY0.405+0.001
TTM0.4055Y0.404+0.001
5Y0.40410Y0.4040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4230.336+0.087
TTM0.4050.330+0.075
YOY0.4050.267+0.138
5Y0.4040.367+0.037
10Y0.4040.378+0.026
1.4.2. Debt to Equity Ratio

Measures if Guiyang Xintian Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Guiyang Xintian Pharmaceutical Co Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 73.3% means that company has ¥0.73 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The MRQ is 0.733. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.683. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.733TTM0.683+0.050
TTM0.683YOY0.680+0.003
TTM0.6835Y0.686-0.003
5Y0.68610Y0.6860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7330.376+0.357
TTM0.6830.398+0.285
YOY0.6800.334+0.346
5Y0.6860.431+0.255
10Y0.6860.476+0.210

2. Market Valuation of Guiyang Xintian Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Guiyang Xintian Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Guiyang Xintian Pharmaceutical Co Ltd to the Biotechnology industry mean.
  • A PE ratio of 17.91 means the investor is paying ¥17.91 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The EOD is 17.616. Based on the earnings, the company is fair priced.
  • The MRQ is 17.910. Based on the earnings, the company is fair priced.
  • The TTM is 41.816. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD17.616MRQ17.910-0.294
MRQ17.910TTM41.816-23.905
TTM41.816YOY51.222-9.406
TTM41.8165Y88.526-46.710
5Y88.52610Y88.5260.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD17.616-2.697+20.313
MRQ17.910-2.422+20.332
TTM41.816-2.709+44.525
YOY51.222-4.116+55.338
5Y88.526-6.257+94.783
10Y88.526-6.478+95.004
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The EOD is 19.555. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 19.881. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -24.516. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD19.555MRQ19.881-0.326
MRQ19.881TTM-24.516+44.397
TTM-24.516YOY-28.150+3.634
TTM-24.5165Y25.847-50.363
5Y25.84710Y25.8470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD19.555-3.344+22.899
MRQ19.881-2.939+22.820
TTM-24.516-3.486-21.030
YOY-28.150-5.592-22.558
5Y25.847-8.464+34.311
10Y25.847-8.872+34.719
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Guiyang Xintian Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.48 means the investor is paying ¥2.48 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Guiyang Xintian Pharmaceutical Co Ltd:

  • The EOD is 2.439. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.480. Based on the equity, the company is underpriced. +1
  • The TTM is 2.732. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.439MRQ2.480-0.041
MRQ2.480TTM2.732-0.252
TTM2.732YOY4.451-1.718
TTM2.7325Y4.602-1.869
5Y4.60210Y4.6020.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4392.198+0.241
MRQ2.4802.042+0.438
TTM2.7322.121+0.611
YOY4.4512.907+1.544
5Y4.6023.682+0.920
10Y4.6024.114+0.488
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Guiyang Xintian Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.1730.200-14%0.125+38%0.271-36%0.271-36%
Book Value Per Share--5.1574.998+3%4.101+26%3.834+35%3.834+35%
Current Ratio--1.2511.229+2%1.344-7%1.567-20%1.567-20%
Debt To Asset Ratio--0.4230.405+4%0.405+5%0.404+5%0.404+5%
Debt To Equity Ratio--0.7330.683+7%0.680+8%0.686+7%0.686+7%
Dividend Per Share--0.0190.069-72%0.027-29%0.036-47%0.036-47%
Eps--0.1790.103+74%0.106+68%0.097+84%0.097+84%
Free Cash Flow Per Share--0.161-0.052+132%-0.089+155%-0.020+112%-0.020+112%
Free Cash Flow To Equity Per Share--0.3300.153+115%-0.044+113%0.062+431%0.062+431%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--1.886--------
Intrinsic Value_10Y_min--1.550--------
Intrinsic Value_1Y_max---0.009--------
Intrinsic Value_1Y_min---0.009--------
Intrinsic Value_3Y_max--0.124--------
Intrinsic Value_3Y_min--0.115--------
Intrinsic Value_5Y_max--0.439--------
Intrinsic Value_5Y_min--0.394--------
Market Cap2912446120.000-2%2964832160.2703162381502.788-6%4198054858.520-29%3901627158.770-24%3901627158.770-24%
Net Profit Margin--0.1660.101+64%0.103+62%0.099+68%0.099+68%
Operating Margin--0.2090.086+144%0.087+140%0.105+99%0.105+99%
Operating Ratio--1.0161.103-8%1.086-6%1.092-7%1.092-7%
Pb Ratio2.439-2%2.4802.732-9%4.451-44%4.602-46%4.602-46%
Pe Ratio17.616-2%17.91041.816-57%51.222-65%88.526-80%88.526-80%
Price Per Share12.580-2%12.79013.638-6%18.125-29%16.846-24%16.846-24%
Price To Free Cash Flow Ratio19.555-2%19.881-24.516+223%-28.150+242%25.847-23%25.847-23%
Price To Total Gains Ratio65.528-2%66.62266.6220%600.435-89%144.614-54%144.614-54%
Quick Ratio--0.6230.579+8%0.714-13%0.736-15%0.736-15%
Return On Assets--0.0200.012+60%0.018+10%0.016+26%0.016+26%
Return On Equity--0.0350.021+64%0.030+15%0.027+30%0.027+30%
Total Gains Per Share--0.1920.269-29%0.152+27%0.307-37%0.307-37%
Usd Book Value--165446820.476160384078.916+3%131472794.783+26%122919240.653+35%122919240.653+35%
Usd Book Value Change Per Share--0.0240.028-14%0.017+38%0.038-36%0.038-36%
Usd Book Value Per Share--0.7140.692+3%0.568+26%0.531+35%0.531+35%
Usd Dividend Per Share--0.0030.010-72%0.004-29%0.005-47%0.005-47%
Usd Eps--0.0250.014+74%0.015+68%0.013+84%0.013+84%
Usd Free Cash Flow--5159822.111-1653845.799+132%-2855340.919+155%-627154.175+112%-627154.175+112%
Usd Free Cash Flow Per Share--0.022-0.007+132%-0.012+155%-0.003+112%-0.003+112%
Usd Free Cash Flow To Equity Per Share--0.0460.021+115%-0.006+113%0.009+431%0.009+431%
Usd Market Cap403082543.008-2%410332770.981437673599.986-6%581010792.419-29%539985198.774-24%539985198.774-24%
Usd Price Per Share1.741-2%1.7701.887-6%2.509-29%2.332-24%2.332-24%
Usd Profit--5727550.7103422838.412+67%4032956.855+42%3277488.649+75%3277488.649+75%
Usd Revenue--34566625.44634396008.780+0%37845967.066-9%31740705.976+9%31740705.976+9%
Usd Total Gains Per Share--0.0270.037-29%0.021+27%0.042-37%0.042-37%
 EOD+4 -4MRQTTM+22 -13YOY+23 -125Y+21 -1410Y+21 -14

3.2. Fundamental Score

Let's check the fundamental score of Guiyang Xintian Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1517.616
Price to Book Ratio (EOD)Between0-12.439
Net Profit Margin (MRQ)Greater than00.166
Operating Margin (MRQ)Greater than00.209
Quick Ratio (MRQ)Greater than10.623
Current Ratio (MRQ)Greater than11.251
Debt to Asset Ratio (MRQ)Less than10.423
Debt to Equity Ratio (MRQ)Less than10.733
Return on Equity (MRQ)Greater than0.150.035
Return on Assets (MRQ)Greater than0.050.020
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Guiyang Xintian Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.575
Ma 20Greater thanMa 5011.989
Ma 50Greater thanMa 10010.902
Ma 100Greater thanMa 20011.733
OpenGreater thanClose12.450
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets2,072,090
Total Liabilities876,665
Total Stockholder Equity1,195,425
 As reported
Total Liabilities 876,665
Total Stockholder Equity+ 1,195,425
Total Assets = 2,072,090

Assets

Total Assets2,072,090
Total Current Assets774,114
Long-term Assets1,297,977
Total Current Assets
Cash And Cash Equivalents 204,566
Short-term Investments 94
Net Receivables 384,999
Inventory 170,333
Other Current Assets 14,121
Total Current Assets  (as reported)774,114
Total Current Assets  (calculated)774,114
+/- 0
Long-term Assets
Property Plant Equipment 651,181
Intangible Assets 161,306
Other Assets 101,812
Long-term Assets  (as reported)1,297,977
Long-term Assets  (calculated)914,299
+/- 383,677

Liabilities & Shareholders' Equity

Total Current Liabilities618,620
Long-term Liabilities258,045
Total Stockholder Equity1,195,425
Total Current Liabilities
Short Long Term Debt 433,000
Accounts payable 88,553
Other Current Liabilities 51,581
Total Current Liabilities  (as reported)618,620
Total Current Liabilities  (calculated)573,134
+/- 45,486
Long-term Liabilities
Long term Debt 200,391
Capital Lease Obligations Min Short Term Debt7,341
Other Liabilities 50,314
Deferred Long Term Liability 85,152
Long-term Liabilities  (as reported)258,045
Long-term Liabilities  (calculated)343,198
+/- 85,152
Total Stockholder Equity
Common Stock231,809
Retained Earnings 644,415
Other Stockholders Equity 140,641
Total Stockholder Equity (as reported)1,195,425
Total Stockholder Equity (calculated)1,016,864
+/- 178,561
Other
Capital Stock231,809
Common Stock Shares Outstanding 231,809
Net Debt 428,824
Net Invested Capital 1,828,816
Net Tangible Assets 1,111,989
Net Working Capital 155,494
Property Plant and Equipment Gross 651,181



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
0
977,057
1,011,151
1,126,444
1,083,648
1,239,995
1,353,439
1,400,652
1,535,934
1,525,743
1,534,080
1,553,224
1,524,427
1,588,466
1,621,254
1,644,702
1,843,851
1,902,559
1,986,087
2,072,090
2,072,0901,986,0871,902,5591,843,8511,644,7021,621,2541,588,4661,524,4271,553,2241,534,0801,525,7431,535,9341,400,6521,353,4391,239,9951,083,6481,126,4441,011,151977,0570
   > Total Current Assets 
0
622,848
598,980
705,332
590,059
684,619
737,092
737,467
812,880
731,541
720,795
653,707
586,829
602,238
615,403
635,502
613,994
638,780
699,343
774,114
774,114699,343638,780613,994635,502615,403602,238586,829653,707720,795731,541812,880737,467737,092684,619590,059705,332598,980622,8480
       Cash And Cash Equivalents 
0
127,101
218,950
255,608
181,656
160,427
292,551
227,315
330,087
226,590
315,921
98,284
72,478
144,358
127,643
89,910
100,668
116,613
128,042
204,566
204,566128,042116,613100,66889,910127,643144,35872,47898,284315,921226,590330,087227,315292,551160,427181,656255,608218,950127,1010
       Short-term Investments 
0
0
0
0
0
175,000
90,000
128,000
118,000
120,000
20,000
130,000
80,000
0
15,000
0
112
105
101
94
94101105112015,000080,000130,00020,000120,000118,000128,00090,000175,00000000
       Net Receivables 
0
151,241
182,874
213,573
293,874
230,451
257,201
287,714
268,228
274,806
272,402
321,868
304,266
284,803
293,441
314,886
304,079
223,976
376,711
384,999
384,999376,711223,976304,079314,886293,441284,803304,266321,868272,402274,806268,228287,714257,201230,451293,874213,573182,874151,2410
       Other Current Assets 
0
160,851
34,744
1,621
20,489
20,212
13,991
16,063
9,744
15,453
9,365
12,029
11,314
18,556
12,183
139
25,792
8,451
16,224
14,121
14,12116,2248,45125,79213912,18318,55611,31412,0299,36515,4539,74416,06313,99120,21220,4891,62134,744160,8510
   > Long-term Assets 
0
354,210
412,172
421,112
493,589
555,375
616,348
663,185
723,054
794,203
813,285
899,517
937,597
986,228
1,005,850
1,009,200
1,229,857
1,263,779
1,286,744
1,297,977
1,297,9771,286,7441,263,7791,229,8571,009,2001,005,850986,228937,597899,517813,285794,203723,054663,185616,348555,375493,589421,112412,172354,2100
       Property Plant Equipment 
250,565
248,611
304,826
326,252
356,568
365,232
371,160
369,352
381,088
400,032
400,733
404,893
463,942
510,585
525,595
525,942
593,747
621,287
640,582
651,181
651,181640,582621,287593,747525,942525,595510,585463,942404,893400,733400,032381,088369,352371,160365,232356,568326,252304,826248,611250,565
       Intangible Assets 
0
90,534
45,055
79,819
117,777
121,388
124,946
128,373
131,943
134,931
134,349
136,967
137,692
139,864
142,121
147,265
149,150
154,594
158,315
161,306
161,306158,315154,594149,150147,265142,121139,864137,692136,967134,349134,931131,943128,373124,946121,388117,77779,81945,05590,5340
       Long-term Assets Other 
0
354,210
412,172
421,112
493,589
555,375
371,160
369,352
0
0
0
0
0
0
0
0
0
0
0
0
000000000000369,352371,160555,375493,589421,112412,172354,2100
> Total Liabilities 
0
308,766
330,981
412,070
374,890
509,036
600,390
622,592
707,636
687,025
687,857
660,544
633,983
644,547
666,496
634,030
714,649
747,022
830,873
876,665
876,665830,873747,022714,649634,030666,496644,547633,983660,544687,857687,025707,636622,592600,390509,036374,890412,070330,981308,7660
   > Total Current Liabilities 
0
284,399
305,297
366,238
332,696
324,785
415,614
434,209
513,639
481,358
481,263
453,354
441,234
469,675
469,716
436,700
498,755
528,754
570,849
618,620
618,620570,849528,754498,755436,700469,716469,675441,234453,354481,263481,358513,639434,209415,614324,785332,696366,238305,297284,3990
       Short-term Debt 
0
207,000
223,000
265,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000265,500223,000207,0000
       Short Long Term Debt 
0
207,000
223,000
265,500
235,813
258,500
341,500
342,000
402,024
366,500
321,853
288,000
268,343
308,000
282,274
257,000
317,367
377,555
388,897
433,000
433,000388,897377,555317,367257,000282,274308,000268,343288,000321,853366,500402,024342,000341,500258,500235,813265,500223,000207,0000
       Accounts payable 
0
31,443
36,705
33,531
30,773
24,894
28,137
35,293
44,811
46,135
57,129
54,522
64,893
81,190
72,374
95,667
95,667
87,367
83,214
88,553
88,55383,21487,36795,66795,66772,37481,19064,89354,52257,12946,13544,81135,29328,13724,89430,77333,53136,70531,4430
       Other Current Liabilities 
0
2,051
0
57,688
14,860
30,137
12,987
45,942
20,964
55,723
57,872
97,793
28,376
68,595
67,275
39,917
39,917
2,243
32,285
51,581
51,58132,2852,24339,91739,91767,27568,59528,37697,79357,87255,72320,96445,94212,98730,13714,86057,68802,0510
   > Long-term Liabilities 
0
24,367
25,684
45,832
42,193
184,251
184,776
188,383
193,997
205,667
206,595
207,191
192,749
174,872
196,780
197,330
215,894
218,267
260,024
258,045
258,045260,024218,267215,894197,330196,780174,872192,749207,191206,595205,667193,997188,383184,776184,25142,19345,83225,68424,3670
       Capital Lease Obligations Min Short Term Debt
0
-207,000
-223,000
-265,500
0
0
0
0
0
11,143
7,024
6,839
6,651
6,447
6,241
6,046
5,721
6,825
4,948
7,341
7,3414,9486,8255,7216,0466,2416,4476,6516,8397,02411,14300000-265,500-223,000-207,0000
       Other Liabilities 
24,910
24,367
25,684
26,832
25,997
25,995
25,359
27,650
34,050
33,459
37,368
36,983
31,305
30,620
31,530
53,493
53,493
0
52,388
50,314
50,31452,388053,49353,49331,53030,62031,30536,98337,36833,45934,05027,65025,35925,99525,99726,83225,68424,36724,910
> Total Stockholder Equity
0
666,535
678,438
713,006
707,444
730,959
753,049
778,060
828,297
838,719
846,222
892,680
890,443
943,919
954,757
1,010,672
1,129,202
1,155,537
1,155,214
1,195,425
1,195,4251,155,2141,155,5371,129,2021,010,672954,757943,919890,443892,680846,222838,719828,297778,060753,049730,959707,444713,006678,438666,5350
   Common Stock
117,096
117,096
117,096
117,096
117,096
117,096
117,096
117,145
117,151
117,156
117,160
117,161
164,048
165,909
165,722
231,969
231,969
0
231,786
231,809
231,809231,7860231,969231,969165,722165,909164,048117,161117,160117,156117,151117,145117,096117,096117,096117,096117,096117,096117,096
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000
   Capital Surplus 00000000000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
23,656
23,656
23,549
60,634
60,622
60,615
60,612
42,605
39,720
39,681
140,686
140,686
0
140,665
140,641
140,641140,6650140,686140,68639,68139,72042,60560,61260,61560,62260,63423,54923,65623,65600000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue994,104
Cost of Revenue-231,053
Gross Profit763,051763,051
 
Operating Income (+$)
Gross Profit763,051
Operating Expense-865,279
Operating Income128,825-102,228
 
Operating Expense (+$)
Research Development31,929
Selling General Administrative501,288
Selling And Marketing Expenses-
Operating Expense865,279533,217
 
Net Interest Income (+$)
Interest Income919
Interest Expense-17,008
Other Finance Cost-1,409
Net Interest Income-17,498
 
Pretax Income (+$)
Operating Income128,825
Net Interest Income-17,498
Other Non-Operating Income Expenses-
Income Before Tax (EBT)107,730128,825
EBIT - interestExpense = -17,008
94,343
111,350
Interest Expense17,008
Earnings Before Interest and Taxes (EBIT)-124,738
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax107,730
Tax Provision-13,388
Net Income From Continuing Ops94,34394,343
Net Income94,343
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-17,498
 

Technical Analysis of Guiyang Xintian Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Guiyang Xintian Pharmaceutical Co Ltd. The general trend of Guiyang Xintian Pharmaceutical Co Ltd is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Guiyang Xintian Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Guiyang Xintian Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 14.03 < 14.11 < 14.33.

The bearish price targets are: 9.66 > 9.59 > 9.59.

Tweet this
Guiyang Xintian Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Guiyang Xintian Pharmaceutical Co Ltd. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Guiyang Xintian Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Guiyang Xintian Pharmaceutical Co Ltd. The current macd is 0.69126152.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Guiyang Xintian Pharmaceutical Co Ltd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Guiyang Xintian Pharmaceutical Co Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Guiyang Xintian Pharmaceutical Co Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Guiyang Xintian Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGuiyang Xintian Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Guiyang Xintian Pharmaceutical Co Ltd. The current adx is 45.89.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Guiyang Xintian Pharmaceutical Co Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Guiyang Xintian Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Guiyang Xintian Pharmaceutical Co Ltd. The current sar is 14.22.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Guiyang Xintian Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Guiyang Xintian Pharmaceutical Co Ltd. The current rsi is 57.57. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Guiyang Xintian Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartGuiyang Xintian Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Guiyang Xintian Pharmaceutical Co Ltd. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Guiyang Xintian Pharmaceutical Co Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Guiyang Xintian Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartGuiyang Xintian Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Guiyang Xintian Pharmaceutical Co Ltd. The current cci is 24.89.

Guiyang Xintian Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartGuiyang Xintian Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Guiyang Xintian Pharmaceutical Co Ltd. The current cmo is 8.738939.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Guiyang Xintian Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartGuiyang Xintian Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Guiyang Xintian Pharmaceutical Co Ltd. The current willr is -64.33823529.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Guiyang Xintian Pharmaceutical Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Guiyang Xintian Pharmaceutical Co Ltd Daily Williams %R ChartGuiyang Xintian Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Guiyang Xintian Pharmaceutical Co Ltd.

Guiyang Xintian Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Guiyang Xintian Pharmaceutical Co Ltd. The current atr is 0.64718211.

Guiyang Xintian Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartGuiyang Xintian Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Guiyang Xintian Pharmaceutical Co Ltd. The current obv is 193,270,518.

Guiyang Xintian Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartGuiyang Xintian Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Guiyang Xintian Pharmaceutical Co Ltd. The current mfi is 65.81.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Guiyang Xintian Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartGuiyang Xintian Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Guiyang Xintian Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-02STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Guiyang Xintian Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Guiyang Xintian Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.575
Ma 20Greater thanMa 5011.989
Ma 50Greater thanMa 10010.902
Ma 100Greater thanMa 20011.733
OpenGreater thanClose12.450
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Guiyang Xintian Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Guiyang Xintian Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Guiyang Xintian Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Guiyang Xintian Pharmaceutical Co Ltd

I send you an email if I find something interesting about Guiyang Xintian Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Guiyang Xintian Pharmaceutical Co Ltd.

Receive notifications about Guiyang Xintian Pharmaceutical Co Ltd in your mailbox!